<DOC>
	<DOCNO>NCT00972595</DOCNO>
	<brief_summary>This study assess bioequivalence Merck clinical trial formulation ondansetron compare non-U.S. market formulation ondansetron .</brief_summary>
	<brief_title>Bioequivalence Two Formulations Ondansetron Healthy Adults ( 0869-106 )</brief_title>
	<detailed_description />
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<criteria>If female , subject pregnant breastfeeding Subject nonsmoker least 6 month Subject good health Subject history high blood pressure , asthma , pulmonary disease , Gastrointestinal ( GI ) abnormalities/peptic ulcer , cardiovascular , liver , neurologic , kidney disease Subject habitual heavy consumer caffeine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>